间断抗雄激素联合手术去势治疗 晚期前列腺癌的疗效分析

The efficacy of surgical castration combined intermittent hormonal therapy for advanced prostate cancer

摘要:

目的 探讨手术去势联合间断抗雄激素药物治疗晚期前列腺癌的疗效和安全性。方法 选取 2009 年8 月—2014 年8 月于佛山市第一人民医院收治的90 例雄激素敏感且失去根治手术机会的晚期前列腺 癌患者作为研究对象，根据患者意愿分为手术组及对照组，其中手术组给予手术去势联合间断抗雄激素药物 治疗；对照组给予常规间歇内分泌治疗。比较两组患者治疗前后的前列腺特异性抗原（PSA）水平、生活质 量评分、疾病无进展生存时间（PFS）、总生存时间（OS）及不良反应情况。结果 手术组患者的PSA 水平， 生活质量评分，PFS 时间和OS 时间优于对照组患者（P <0.05），手术组患者性欲减退发生率高于对照组患者 （P <0.05）；两组患者潮热、骨质疏松、乳房胀痛的发生率比较，差异无统计学意义（P >0.05）。结论 手术 去势联合间断抗雄激素药物治疗晚期前列腺的疗效确切，值得临床推广。

Abstract:

Objective To investigate the efficacy and security of surgical castration combined intermittent hormonal therapy for the advanced prostate cancer. Methods From Aug. 2009 to Aug. 2014, 90 patients with advanced hormone-sensitive prostate cancer were divided into surgical and control groups according to the operation will. Surgical group contains 36 patients who received surgical castration combined intermittent hormonal therapy, and control group contains 54 patients who received intermittent hormonal therapy. The PSA level, quality of life scores, PFS time, OS time and side effects were collected and compared. Results The PSA level、quality of life scores, PFS time and OS time of patients in surgical group are better than those in control group (P < 0.05), while the incidence of asexuality is higher in the surgical group (P < 0.05). There is no significant difference of other side effects such as hot flashes, osteoporosis and pain in breast. Conclusions Surgical castration combined intermittent hormonal therapy is safe and effective for the advanced prostate cancer.